NO20090908L - Ikke rodskjaer fremkallende nikotinsyre analoger og fremgangsmater for bruk derav - Google Patents
Ikke rodskjaer fremkallende nikotinsyre analoger og fremgangsmater for bruk deravInfo
- Publication number
- NO20090908L NO20090908L NO20090908A NO20090908A NO20090908L NO 20090908 L NO20090908 L NO 20090908L NO 20090908 A NO20090908 A NO 20090908A NO 20090908 A NO20090908 A NO 20090908A NO 20090908 L NO20090908 L NO 20090908L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- pharmaceutically acceptable
- relates
- methods
- variety
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Et aspekt av foreliggende oppfinnelse ang år substituerte pyridiner og farmasøytisk akseptable salter derav som er aktive overfor et antall pattedyrsykdommer. Et annet aspekt ifølge oppfinnelsen ang år en farmasøytisk sammensetning som innbefatter en forbindelse ifølge oppfinnelsen eller et farmasøytisk akseptabelt salt derav; og en farmasøytisk akseptabel eksipient. Foreliggende oppfinnelse angår også fremgangs-m åter for behandling av et antall pattedyrsykdommer eller tilstander, som inkluderer, men er ikke begrenset til, hyperlipidemi, hyperkolesterolemi, aterosklerose, koronar arterie sykdom, kongestiv hjertesvikt, kardiovaskulær sykdom, hypertensjon, koronar arterie sykdom, angina, pellagra, Hartnup' s syndrom, karsinoid syndrom, arterial okklusiv sykdom, fedme, hypotyroidisme, vasokonstriksjon, osteoartritt, reumatoid artritt, diabetes, Alzheimer' s sykdom, lipodystrofi eller dyslipidemi, heving av serum høy tetthets lipoprotein (HDL) nivåer og redusering av serum lav tetthets lipoprotein (LDL) niv åer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83519406P | 2006-08-03 | 2006-08-03 | |
PCT/US2007/074960 WO2008016968A2 (en) | 2006-08-03 | 2007-08-01 | Non-flushing niacin analogues, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090908L true NO20090908L (no) | 2009-05-04 |
Family
ID=38997834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090908A NO20090908L (no) | 2006-08-03 | 2009-02-27 | Ikke rodskjaer fremkallende nikotinsyre analoger og fremgangsmater for bruk derav |
Country Status (12)
Country | Link |
---|---|
US (4) | US8377971B2 (no) |
EP (1) | EP2054386B1 (no) |
JP (1) | JP5270545B2 (no) |
KR (1) | KR101403887B1 (no) |
CN (1) | CN101522623B (no) |
AU (1) | AU2007281212B8 (no) |
BR (1) | BRPI0714793A2 (no) |
CA (1) | CA2659747C (no) |
IL (1) | IL196763A (no) |
MX (1) | MX2009001279A (no) |
NO (1) | NO20090908L (no) |
WO (1) | WO2008016968A2 (no) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5270545B2 (ja) * | 2006-08-03 | 2013-08-21 | タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ | フラッシングのないナイアシン類似体およびそれらの使用法 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
WO2011163612A1 (en) | 2010-06-24 | 2011-12-29 | Trustees Of Tufts College | Niacin mimetics, and methods of use thereof |
JP5925771B2 (ja) | 2010-06-24 | 2016-05-25 | トラスティーズ オブ タフツ カレッジ | ナイアシン模倣体、およびその使用方法 |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013103842A1 (en) | 2012-01-06 | 2013-07-11 | Michigan Life Therapeutics, Llc | Methods of reducing risk of cardiovascular disease |
US10011594B2 (en) | 2015-06-03 | 2018-07-03 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists |
KR20180073597A (ko) | 2015-11-06 | 2018-07-02 | 젬파이어 세러퓨틱스 인코포레이티드 | 혼합 이상지질혈증의 치료 |
PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
EP0013153B1 (en) | 1978-12-27 | 1982-12-22 | Beecham Group Plc | 6-amino pyridine carboxylic acid derivatives, a process for their preparation and pharmaceutical compositions containing them |
CA1155842A (en) * | 1980-03-29 | 1983-10-25 | Thomas H. Brown | Compounds |
US4444775A (en) * | 1981-06-22 | 1984-04-24 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridines |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
WO1991015484A1 (de) * | 1990-04-10 | 1991-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridine als arzneimittel |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
EP1114048A1 (en) * | 1998-09-16 | 2001-07-11 | Agnès Bombrun | Carboline derivatives as cgmp phosphodiesterase inhibitors |
CA2456096A1 (en) * | 2001-08-01 | 2003-02-13 | Mochida Pharmaceutical Co., Ltd. | Novel amine derivative having human .beta.-tryptase inhibitory activity and medecine containing the same |
WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
WO2008011131A2 (en) * | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
TW200418835A (en) * | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
CN1972914A (zh) * | 2004-03-31 | 2007-05-30 | 詹森药业有限公司 | 作为组胺h3受体配合体的非咪唑杂环化合物 |
EP1765335B1 (en) * | 2004-07-07 | 2009-11-25 | Merck & Co., Inc. | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
JP2006056884A (ja) * | 2004-07-23 | 2006-03-02 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
CN101056635A (zh) * | 2004-11-04 | 2007-10-17 | 默克公司 | 烟酸受体激动剂、含有该化合物的组合物及治疗方法 |
AU2005309737A1 (en) * | 2004-11-23 | 2006-06-01 | Merck Sharp & Dohme Corp. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
JP2008540433A (ja) | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシドヒドロラーゼインヒビター及びその使用方法 |
EP1879575A2 (en) | 2005-05-09 | 2008-01-23 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
DE102005062379A1 (de) | 2005-12-23 | 2007-06-28 | Basf Ag | Carbamatgruppenhaltiger Co-Vernetzer |
JP5270545B2 (ja) * | 2006-08-03 | 2013-08-21 | タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ | フラッシングのないナイアシン類似体およびそれらの使用法 |
-
2007
- 2007-08-01 JP JP2009523035A patent/JP5270545B2/ja not_active Expired - Fee Related
- 2007-08-01 EP EP07799967.0A patent/EP2054386B1/en not_active Not-in-force
- 2007-08-01 CN CN200780037196XA patent/CN101522623B/zh not_active Expired - Fee Related
- 2007-08-01 KR KR1020097004319A patent/KR101403887B1/ko not_active IP Right Cessation
- 2007-08-01 WO PCT/US2007/074960 patent/WO2008016968A2/en active Application Filing
- 2007-08-01 BR BRPI0714793-7A patent/BRPI0714793A2/pt not_active IP Right Cessation
- 2007-08-01 MX MX2009001279A patent/MX2009001279A/es active IP Right Grant
- 2007-08-01 AU AU2007281212A patent/AU2007281212B8/en not_active Ceased
- 2007-08-01 CA CA2659747A patent/CA2659747C/en active Active
- 2007-08-01 US US12/376,238 patent/US8377971B2/en active Active
-
2009
- 2009-01-28 IL IL196763A patent/IL196763A/en not_active IP Right Cessation
- 2009-02-27 NO NO20090908A patent/NO20090908L/no not_active Application Discontinuation
-
2012
- 2012-12-14 US US13/715,242 patent/US8889720B2/en not_active Expired - Fee Related
-
2014
- 2014-10-15 US US14/514,995 patent/US9193708B2/en active Active
-
2015
- 2015-11-04 US US14/932,506 patent/US9511060B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20090035034A (ko) | 2009-04-08 |
EP2054386A4 (en) | 2010-03-17 |
BRPI0714793A2 (pt) | 2015-06-16 |
CA2659747C (en) | 2015-09-08 |
CN101522623A (zh) | 2009-09-02 |
US20150099787A1 (en) | 2015-04-09 |
AU2007281212A1 (en) | 2008-02-07 |
CA2659747A1 (en) | 2008-02-07 |
WO2008016968A2 (en) | 2008-02-07 |
MX2009001279A (es) | 2009-02-11 |
US20090312355A1 (en) | 2009-12-17 |
US9193708B2 (en) | 2015-11-24 |
AU2007281212A8 (en) | 2013-02-28 |
IL196763A0 (en) | 2009-11-18 |
JP5270545B2 (ja) | 2013-08-21 |
JP2009545616A (ja) | 2009-12-24 |
AU2007281212B2 (en) | 2012-11-01 |
KR101403887B1 (ko) | 2014-06-20 |
EP2054386B1 (en) | 2014-10-08 |
US20130217714A1 (en) | 2013-08-22 |
US9511060B2 (en) | 2016-12-06 |
US20160151343A1 (en) | 2016-06-02 |
CN101522623B (zh) | 2013-06-12 |
WO2008016968A3 (en) | 2008-12-18 |
US8889720B2 (en) | 2014-11-18 |
EP2054386A2 (en) | 2009-05-06 |
US8377971B2 (en) | 2013-02-19 |
AU2007281212B8 (en) | 2013-02-28 |
IL196763A (en) | 2014-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090908L (no) | Ikke rodskjaer fremkallende nikotinsyre analoger og fremgangsmater for bruk derav | |
JP2008521829A5 (no) | ||
ES2292770T3 (es) | Derivados de fenilpirazoles en calidad de inhibidores de epoxido hidrolasa solubles. | |
JP2008521831A5 (no) | ||
NO20076450L (no) | Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi | |
NO20032861L (no) | Heteroarylurea nevropeptid Y Y5-reseptorantagonister | |
NO20084318L (no) | Inhibitorer av II-beta-hydroksystereoid dehydrogenase I | |
HRP20160303T1 (hr) | Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi | |
JP2013010793A5 (no) | ||
CY1115776T1 (el) | Τροποποιητες του υποδοχεα της προστακυκλινη (pg12) χρησιμοι για τη θεραπευτικη αγωγη διαταραχων που σχετιζονται με αυτον | |
NO20062968L (no) | Organiske forbindelser | |
EA201071035A1 (ru) | Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения | |
NO20080058L (no) | Pyridazinonderivativer som tyroidhormon reseptoragonister | |
WO2005051322A3 (en) | Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts | |
WO2006128056A3 (en) | Novel phosphinic acid-containing thyromimetics | |
RU2009110442A (ru) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой | |
CY1105479T1 (el) | Παραγωγα τετραζολιου και μεθοδοι αντιμετωπισης σχετιζομενων με τον μεταβολισμο διαταραχων με αυτα | |
ATE424821T1 (de) | Pyrrolopyridin-2-karbonsäureamide | |
CY1115573T1 (el) | Τροποποιημενα ενζυμα λεκιθινοχοληστερολικης ακυλοτρανσφερασης | |
NZ591601A (en) | Therapeutic compositions containing macitentan and a prostacyclin receptor agonist | |
TWI256890B (en) | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | |
RU2007123614A (ru) | Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина | |
NO20076424L (no) | N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser | |
JP2013529645A5 (no) | ||
Li et al. | Structure-guided design of novel, potent, and selective macrocyclic plasma kallikrein inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |